Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

MLA

Scott, A. M., et al. “Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients with Metastatic Melanoma: Results of a Phase I Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 19, no. 19, Oct. 2001, pp. 3976–87. EBSCOhost, https://doi.org/10.1200/JCO.2001.19.19.3976.

APA

Scott, A. M., Lee, F. T., Hopkins, W., Cebon, J. S., Wheatley, J. M., Liu, Z., Smyth, F. E., Murone, C., Sturrock, S., MacGregor, D., Hanai, N., Inoue, K., Yamasaki, M., Brechbiel, M. W., Davis, I. D., Murphy, R., Hannah, A., Lim-Joon, M., Chan, T., … Old, L. J. (2001). Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 19(19), 3976–3987. https://doi.org/10.1200/JCO.2001.19.19.3976

Chicago

Scott, A M, F T Lee, W Hopkins, J S Cebon, J M Wheatley, Z Liu, F E Smyth, et al. 2001. “Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients with Metastatic Melanoma: Results of a Phase I Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 19 (19): 3976–87. doi:10.1200/JCO.2001.19.19.3976.